Worldwide NFT, Inc. (WNFT) has entered into an agreement with Forwardly, Inc., whereby Forwardly will purchase an WNFT warrant providing the right to purchase 5 million WNFT warrant shares at $.32 per warrant share. The warrant must be exercised either in full or in part within two years of issuance. Forwardly will pay WNFT $200,000 for this. WNFT is in the process of negotiating up to $5 million in equity financing to be used as operational capital by successful acquisition or reverse merger targets.

WNFT is now in discussions/negotiations to acquire assets in the NFT (Non-Fungible Tokens) and Blockchain space. NFTs can be exchanged or traded equivalently like other cryptographic assets as they are financial securities consisting of digital data stored in a blockchain, a form of distributed ledger. The ownership of an NFT is recorded in the blockchain, and can be transferred by the owner, allowing NFTs to be sold and traded.

Forwardly, Inc. (OTCMKT: FORW) has purchased $250,000 in BLOCKS tokens directly from Blocks DAO, LLC. Although the tokens were purchased from treasury, Forwardly paid the quoted market price at the time of the purchase, using cash the company had on hand.

Forwardly President, George Sharp stated, “We believe that Blockchain is the future of everything and together with its investment in HUMBL, Inc., this acquisition of BLOCKS gives Forwardly a foothold in that future. It is Forwardly’s intention to hold this asset long term. We are also considering other investments in the blockchain industry.”

HUMBL, Inc. is a Web 3, Blockchain platofrm company working to simplify blockchain use cases across verticals like mobile payments, ticketing, NFTs and real estate. Forwardly, Inc.  hold an investment of not less than 10 million shares of HUMBL, Inc (OTCQB:HMBL). through the partial exercise of a warrant the company holds.

• a wholly owned subsidiary corporation

June 1, 2020 Forwardly, Inc. formed "Breathe Medical Devices, Inc.", a wholly owned Wyoming corporation.

This subsidiary will be the operating arm for Forwardly's recent acquisition of the exclusive US distribution rights to VitaCaeli™ (LifeAir), a patent pending, non-invasive ventilator currently under development by Ligand Innovation Global, a Canadian corporation. A newer iteration of the VitaCaeli™ (LifeAir) ventilator has been engineered for a summer 2022 submission to the US Food and Drug Administration ("FDA") and Canada Health in the hopes of obtaining fast track approval. A demonstration of a prototype of the VitaCaeli™ (LifeAir) ventilator is available for viewing at www.LigandGlobal.com 

The new subsidiary will at least initially be managed by Mr. Sharp, however, the company is currently reviewing the new asset with several prominent doctors and has formed a Medical Advisory Board.

Update: As of April 9, 2021 – Forwardly, Inc. owns 33.3% of Ligand Global Innovation.